Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes

Show simple item record

dc.contributor.author Newman, M.J.
dc.contributor.author Walker, L.E.
dc.contributor.author Vang, L.
dc.contributor.author Shen, X.
dc.contributor.author Livingston, B.D.
dc.contributor.author Post, P.
dc.contributor.author Sette, A.
dc.contributor.author Godin, C.S.
dc.date.accessioned 2012-05-17T15:47:07Z
dc.date.accessioned 2017-10-19T12:11:07Z
dc.date.available 2012-05-17T15:47:07Z
dc.date.available 2017-10-19T12:11:07Z
dc.date.issued 2009
dc.identifier.citation Vaccine Journal 27(50): 7087-95 en_US
dc.identifier.uri http://197.255.68.203/handle/123456789/1485
dc.description.abstract Coordinated interactions between helper and cytotoxic T-lymphocytes (HTL and CTL) are needed for optimal effector cell functions and the establishment of immunological memory. We, therefore, designed a mixed format vaccine based on the use of highly conserved HIV-derived T-lymphocyte epitopes wherein the HTL epitopes were delivered as a recombinant protein and the CTL epitopes which were encoded in a DNA vaccine plasmid. Immunogenicity testing in HLA transgenic mice and GLP preclinical safety testing in rabbits and guinea pigs were used to document the utility of this approach and to support Phase 1 trial clinical testing. Both vaccine components were immunogenic and safely co-administered. en_US
dc.language.iso en en_US
dc.publisher Vaccine Journal en_US
dc.title Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes en_US
dc.type Article en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search UGSpace


Browse

My Account